Estudio de efectividad y seguridad de los agentes estimulantes de la eritropoyesis en el tratamiento de la anemia asociada a enfermedad renal crónica. Análisis de los factores que influyen en la respuesta

Pérez Diez, Cristina; Navarro Aznárez, Herminia; Lou Arnal, Luis Miguel; Abad Sazatornil, Mª Reyes.
Pharm. care Esp ; 23(4): 6-18, Ago 13, 2021. ilus, tab
Artículo en Español | IBECS (España) | ID: ibc-215956

Documentos relacionados

  1. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.
  2. Evaluación de la indicación de los agentes estimulantes de la eritropoyesis en el tratamiento de la anemia asociada a enfermedad renal crónica
  3. Comparative Effects of Pegylated Erythropoietin and Darbepoetin Alfa on Erythropoietin Hyporesponsive Anemia of Patients with Chronic Kidney Disease on Maintenance Hemodialysis.
  4. Treatment satisfaction with molidustat in CKD-related anemia in non-dialysis patients: a post-hoc analysis of two clinical trials.
  5. Initial responsiveness to darbepoetin alfa and its contributing factors in non-dialysis chronic kidney disease patients in Japan.
  6. Overall Adverse Event Profile of Vadadustat versus Darbepoetin Alfa for the Treatment of Anemia Associated with Chronic Kidney Disease in Phase 3 Trials.
  7. Subcutaneous C.E.R.A. for the Maintenance Treatment of Anemia in Pediatric Patients With CKD: A Phase 2, Open-Label, Single-Arm, Multicenter Study.
  8. Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD.
  9. Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients.
  10. Uptake of evidence by physicians: De-adoption of erythropoiesis-stimulating agents after the TREAT trial.